等待開盤 04-01 09:30:00 美东时间
+0.390
+6.91%
ElectroCore, Inc. announced the appointment of Seth Abrams as VP of Sales and Michael Fox as Chief Operating Officer. They will receive 30,000 and 70,000 RSUs respectively, subject to vesting over three years. The company specializes in non-invasive bioelectronic technologies for health and wellness, including products for chronic pain management.
03-31 12:00
U.S. Patent No. 12,208,263, entitled "Devices and Methods for Vagal Nerve Stimulation" was issued on January 28, 2026U.S. Patent No. 12,213,795, entitled "Devices and Methods for Remote Therapy and Patient Monitoring"
03-30 20:04
electroCore获得两项新美国专利,加强其非侵入式迷走神经刺激技术的知识产权组合,涵盖设备、方法及远程监测系统。这些专利扩大了公司产品组合的保护范围,并将其专利保护延长至2039年,巩固其在头痛和 wellness 领域的市场地位。
03-30 12:00
Electrocore (($ECOR)) has held its Q4 earnings call. Read on for the main highl...
03-21 08:02
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据electroCore业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 2025年全年营收达到3,200万美元,同比增长27% - 第四季度营收920万美元,同比增长31%,创历史新高 - VA渠道营收2,600万美元,同比增长23% - 一般健康产品营收550万美元,同比增长97% - Truvaga产品营收540万美元,同比增长93% **盈利能力:** - 毛利润2,780万美元 - 毛利率87%,较上年的5%大幅提升 - 净亏损1,400万美元(每股1.65美元),上年净亏损1,190万美元(每股1.59
03-20 12:10
electroCore (NASDAQ:ECOR) sees FY2026 sales of $41.642 million vs $42.089 million analyst estimate.
03-20 04:35
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.41) by 16.46 percent. This is a 15 percent increase over losses of $(0.40) per share from the same
03-20 04:22
electroCore, Inc. (Nasdaq: ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced full year 2025 financial results.Announced Chief Executive Officer, Dan Goldberger will retire
03-20 04:14
- ElectroCore announces 2025 full-year net sales of $32.0 million, up 27% from $25.2 million in 2024, driven by 25% growth in US prescription business and 97% increase in general wellness sales. - CEO Dan Goldberger to retire effective April 1, 2026; Joshua Lev named interim President and CFO; Michael Fox joins as COO. - 2026 revenue guidance targets 30% annual growth. - Conference call and webcast scheduled for March 19, 2026, at 4:30 PM EDT.
03-19 20:05
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11